Savara Inc.
SVRA
$0.08
Change (1 day)
$5.70
Year High
$2.82
Year Low
Categories
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Stock split history for Savara Inc. (SVRA)
Savara Inc. stock (symbol: SVRA) underwent a total of 2 stock splits.
The most recent stock split occured on Apr 26, 2010.
Annual Revenue
| Date | Splite | Multiple |
|---|---|---|
| 2010-04-26 | 1:25 | 1 |
| 2002-06-11 | 251:500 | 251 |